Sorrento plans phase II trial for COVID-19 treatment

By The Science Advisory Board staff writers

July 20, 2020 -- Sorrento Therapeutics received clearance from the U.S. Food and Drug Administration to initiate a phase II clinical trial evaluating abivertinib for treatment of moderate and severe COVID-19 patients.

The tyrosine kinase inhibitor, licensed from Acea Therapuetics, is a potent immunomodulator that inhibits pro-inflammatory cytokine production, including interleukin 1 beta (IL-1beta), IL-6, and tumor necrosis factor alpha (TNF alpha). These cytokines have been associated with cytokine storms and COVID-19 progression with poor outcomes in patients with acute respiratory distress syndrome (ARDS).

The phase II, double-blind, randomized clinical study (NCT04440007) will be initially conducted in the U.S.

Abivertinib has previously been studied in over 600 patients with various oncologic indications.

Sorrento moves forward with COVID-19 prophylactic drug
Sorrento has completed preclinical testing of STI-4398 (COVIDTRAP), reporting positive results on the protein's ability to neutralize and inhibit the...
Sorrento, Mount Sinai to develop targeted SARS-CoV-2 antibody treatment
Sorrento Therapeutics and Mount Sinai Health System have joined forces to develop an antibody therapy called COVI-Shield to treat COVID-19.

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter